Latest Period
Q4 2025
Security Snapshot
Indivior Pharmaceuticals Inc - Common Stock (INDV) Institutional Ownership
CUSIP: G4766E116
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
245
Shares (Excl. Options)
113,007,616
Price
$35.88
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- INDV on Nasdaq
- Shares outstanding
- 122,058,565
- Price per share
- $32.28
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 113,007,616
- Total reported value
- $4,052,441,161
- % of total 13F portfolios
- 0.01%
- Share change
- -4,536,824
- Value change
- -$19,858,368
- Number of holders
- 245
- Price from insider filings
- $32.28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- INDV - Indivior Pharmaceuticals Inc - Common Stock is tracked under CUSIP G4766E116.
- 245 institutions reported positions in Q4 2025.
- 11 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 245 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $4,052,441,161 to $1,309,055.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 245 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP G4766E116?
CUSIP G4766E116 identifies INDV - Indivior Pharmaceuticals Inc - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G4766E116:
Significant Owners of Indivior Pharmaceuticals Inc - Common Stock (INDV) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 14% | +107% | $638,884,065 | +$335,082,637 | 17,806,183 | +110% | BlackRock, Inc. | 31 Dec 2025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6% | $272,463,211 | 7,994,836 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| Oaktree Capital Holdings, LLC | 5.7% | -19% | $232,808,746 | -$53,592,755 | 7,108,664 | -19% | Oaktree Capital Holdings, LLC | 24 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4% | $222,327,725 | 6,523,720 | Vanguard Capital Management | 31 Mar 2026 | |||
| FULLER & THALER ASSET MANAGEMENT, INC. | 5.1% | $216,632,146 | 6,371,534 | Fuller & Thaler Asset Management, Inc. | 31 Dec 2025 | |||
| Madison Avenue Partners, LP | 5% | -17% | $213,537,068 | -$39,360,134 | 6,280,502 | -16% | Madison Avenue International LP | 31 Dec 2025 |
| Two Seas Capital LP | 5% | -12% | $203,438,218 | -$27,837,500 | 6,211,854 | -12% | Two Seas Capital LP | 23 Dec 2025 |
| MILLENNIUM MANAGEMENT LLC | 3.8% | +90% | $158,472,151 | +$77,320,782 | 4,806,556 | +95% | Millennium Management LLC | 17 Mar 2026 |
| MORGAN STANLEY | 3.7% | $53,976,433 | 4,665,206 | Morgan Stanley | 31 Mar 2025 | |||
| Flynn James E | 3.7% | -60% | $111,255,547 | -$143,518,681 | 4,614,498 | -56% | Deerfield Mgmt, L.P. | 10 Nov 2025 |
| GOLDMAN SACHS GROUP INC | 2.9% | -46% | $122,142,647 | -$99,940,892 | 3,592,431 | -45% | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 |
As of 31 Dec 2025, 245 institutional investors reported holding 113,007,616 shares of Indivior Pharmaceuticals Inc - Common Stock (INDV). This represents 93% of the company’s total 122,058,565 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Indivior Pharmaceuticals Inc - Common Stock (INDV) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15% | 18,230,539 | +109% | 0.01% | $654,111,738 |
| OAKTREE CAPITAL MANAGEMENT LP | 5.8% | 7,108,644 | 0% | 4.1% | $255,058,964 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 5.2% | 6,371,534 | +101% | 0.77% | $228,610,629 |
| VANGUARD GROUP INC | 4.5% | 5,473,891 | +58% | 0% | $196,403,209 |
| Two Seas Capital LP | 4.2% | 5,109,198 | -51% | 11% | $183,318,024 |
| STATE STREET CORP | 3.8% | 4,659,281 | +66% | 0.01% | $167,175,002 |
| MORGAN STANLEY | 3.6% | 4,377,774 | -22% | 0.01% | $157,074,532 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.8% | 3,393,063 | -51% | 1.6% | $121,743,100 |
| GOLDMAN SACHS GROUP INC | 2.6% | 3,177,867 | -52% | 0.02% | $114,021,868 |
| ACADIAN ASSET MANAGEMENT LLC | 2.5% | 3,085,113 | +7% | 0.18% | $109,505,000 |
| CITADEL ADVISORS LLC | 2.5% | 3,061,902 | +17% | 0.07% | $109,861,044 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 2,837,824 | -0.65% | 0.01% | $101,840,214 |
| Divisadero Street Capital Management, LP | 2.3% | 2,784,786 | -17% | 5.7% | $99,918,122 |
| MANGROVE PARTNERS IM, LLC | 2.2% | 2,746,009 | +0.13% | 8% | $98,526,803 |
| Newtyn Management, LLC | 2.1% | 2,534,538 | -40% | 9.6% | $90,939,223 |
| MILLENNIUM MANAGEMENT LLC | 1.9% | 2,337,685 | +1.2% | 0.06% | $83,876,138 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.9% | 2,304,545 | 0.14% | $82,687,075 | |
| BARCLAYS PLC | 1.5% | 1,878,157 | -12% | 0.03% | $67,388,274 |
| Point72 Asset Management, L.P. | 1.5% | 1,821,872 | -36% | 0.1% | $65,368,767 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.4% | 1,705,900 | 0.04% | $61,207,692 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1% | 1,243,593 | +8.3% | 0.01% | $44,620,117 |
| GOLDENTREE ASSET MANAGEMENT LP | 1% | 1,241,482 | -30% | 2.4% | $44,460,908 |
| SOROS FUND MANAGEMENT LLC | 0.95% | 1,154,452 | -15% | 0.56% | $41,421,738 |
| DIMENSIONAL FUND ADVISORS LP | 0.92% | 1,118,169 | +86% | 0.01% | $40,118,826 |
| GENDELL JEFFREY L | 0.9% | 1,096,343 | +4.8% | 0.69% | $39,336,787 |
Institutional Holders of Indivior Pharmaceuticals Inc - Common Stock (INDV) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 42,914 | $1,309,055 | -$257,009,390 | $32.28 | 2 |
| 2025 Q4 | 113,007,616 | $4,052,441,161 | -$19,858,368 | $35.88 | 245 |
| 2025 Q3 | 110,811,392 | $2,670,071,230 | +$380,369,121 | $24.11 | 196 |
| 2025 Q2 | 106,959,206 | $1,577,697,144 | +$260,685,760 | $14.74 | 119 |
| 2025 Q1 | 91,341,313 | $865,955,709 | +$119,981,356 | $9.53 | 115 |
| 2024 Q4 | 77,790,536 | $974,764,447 | +$68,457,241 | $12.43 | 112 |
| 2024 Q3 | 71,540,427 | $699,253,141 | +$54,237,351 | $9.75 | 100 |
| 2024 Q2 | 64,306,768 | $1,024,584,616 | -$11,033,099 | $16.12 | 95 |
| 2024 Q1 | 63,276,125 | $1,352,112,050 | +$24,497,831 | $21.42 | 86 |
| 2023 Q4 | 63,746,436 | $970,147,653 | -$75,831,576 | $15.27 | 69 |
| 2023 Q3 | 67,913,856 | $1,531,662,383 | +$134,844,672 | $21.99 | 72 |
| 2023 Q2 | 61,447,059 | $1,522,893,399 | +$1,522,893,346 | $23.80 | 56 |